A parenteral DNA vaccine protects against pneumonic plague.

Veterinary Molecular Biology, Montana State University, Bozeman, MT 59717, USA.
Vaccine (Impact Factor: 3.49). 02/2010; 28(18):3219-30. DOI: 10.1016/j.vaccine.2010.02.022
Source: PubMed

ABSTRACT The chemokine, lymphotactin (LTN), was tested as a molecular adjuvant using bicistronic DNA vaccines encoding the protective Yersinia capsular (F1) antigen and virulence antigen (V-Ag) as a F1-V fusion protein. The LTN-encoding F1-V or V-Ag vaccines were given by the intranasal (i.n.) or intramuscular (i.m.) routes, and although serum IgG and mucosal IgA antibodies (Abs) were induced, F1-Ag boosts were required for robust anti-F1-Ag Abs. Optimal efficacy against pneumonic plague was obtained in mice i.m.-, not i.n.-immunized with these DNA vaccines. These vaccines stimulated elevated Ag-specific Ab-forming cells and mixed Th cell responses, with Th17 cells markedly enhanced by i.m. immunization. These results show that LTN can be used as a molecular adjuvant to enhance protective immunity against plague.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: DNA vaccines have been on the scientific horizon since 1992, yet the past decade of clinical study has been precarious, with most trials exhibiting excellent safety, yet poor immune responses in humans. Despite the initial disappointments of immunogenicity observed in early clinical trials, the advantageous properties of plasmid DNA as a vaccine strategy over existing technologies continued to drive the field forward. Recently, non- human primate preclinical models as well as data generated in a few clinical trials have suggested that there are significant improvements in immunogenicity by the renewed enhanced DNA platform. This is due to a host of new technological improvements that together have improved vaccine antigen expression, delivery, and formulation resulting in improved immune potency. Improvements in plasmid delivery by modalities including the gene gun, biojector and most recently electroporation (EP) in particular, in combination with other technological developments such as species-specific codon optimization, improved RNA structural design, incorporation of novel leader sequences, novel formulations and adjuvant strategies have had a significant effect on immune outcome in relevant primate models and now humans. This new generation of DNA vaccines will likely have a more prominent role in vaccine clinical research.
    08/2011: pages 145-162;
  • Oral Oncology 07/2011; 47. DOI:10.1016/j.oraloncology.2011.06.096 · 3.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present paper develops a bilinear constitutive relation for material at fracture tip based on the cohesive zone model and the J-integral theory. In this bilinear constitutive relation, the stress linearly decreases rather than suddenly drops down to zero at the post-peak stage. The slope of stress degradation is related to the critical J-integral of material and the element size. By this bilinear constitutive relation, the tensile and mixed fracture propagation can be well simulated for the strain energy release rate can be preserved with element size decreasing. The simulation results are almost free of the element size sensitivity. The present model and its implementation are very simple. For the elements at fracture tip, the derived bilinear constitutive relation is adopted while for the rest elements, the ideal elastic-brittle model is adopted. For the fracture propagation is represented by the deterioration of stiffness through constitutive relation, no separate fracture criterion is needed, which makes the evaluation of the fracture propagation by separate fracture criterion and the mesh modification after each load step unnecessary. The simulation examples of tensile and mixed fracture suggest that the present method is valid and highly efficient.
    International Journal of Rock Mechanics and Mining Sciences 02/2011; 48(2):294-304. DOI:10.1016/j.ijrmms.2010.08.019 · 1.42 Impact Factor

Full-text (2 Sources)

Available from
Jun 12, 2014